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Abstract
To study expression and function of methylthioadenosine phosphorylase (MTAP), the rate-limiting enzyme in the
methionine and adenine salvage pathway, in chronic liver disease.
Design: MTAP expression was analyzed by qRT-PCR, Western blot and immunohistochemical analysis. Levels of
MTA were determined by liquid chromatography-tandem mass spectrometry.
Results: MTAP was downregulated in hepatocytes in murine fibrosis models and in patients with chronic liver
disease, leading to a concomitant increase in MTA levels. In contrast, activated hepatic stellate cells (HSCs) showed
strong MTAP expression in cirrhotic livers. However, also MTA levels in activated HSCs were significantly higher
than in hepatocytes, and there was a significant correlation between MTA levels and collagen expression in diseased
human liver tissue indicating that activated HSCs significantly contribute to elevated MTA in diseased livers. MTAP
suppression by siRNA resulted in increased MTA levels, NFκB activation and apoptosis resistance, while
overexpression of MTAP caused the opposite effects in HSCs. The anti-apoptotic effect of low MTAP expression and
high MTA levels, respectively, was mediated by induced expression of survivin, while inhibition of survivin abolished
the anti-apoptotic effect of MTA on HSCs. Treatment with a DNA demethylating agent induced MTAP and reduced
survivin expression, while oxidative stress reduced MTAP levels but enhanced survivin expression in HSCs.
Conclusion: MTAP mediated regulation of MTA links polyamine metabolism with NFκB activation and apoptosis in
HSCs. MTAP and MTAP modulating mechanisms appear as promising prognostic markers and therapeutic targets
for hepatic fibrosis.
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Introduction
Impaired expression and function of genes regulating
polyamine metabolic pathways have been described in chronic
liver disease and these alterations may contribute to the
progression of hepatic fibrosis and malignant transformation
[1–3]. Methylthioadenosine phosphorylase (MTAP) is the rate-
limiting enzyme in methionine and adenine salvage pathways.
MTAP catalyzes the phosphorylation of 5'-deoxy-5'-
methylthioadenosine (MTA), which is a by-product of
polyamine synthesis, to yield adenine and methylthioribose-1-
phosphate (MTR-1P). MTR-1P is then converted in a series of
enzymatic reactions to regenerate methionine [4]. Furthermore,
MTAP regulates polyamine synthesis, as MTA acts an inhibitor
of several key enzymes in this pathway [5]. Consistent with its
central metabolic role, MTAP expression is high in normal liver
tissue [6]. In HCC, on the other hand, loss or downregulation of
MTAP leads to accumulation of MTA, which promotes
tumorigenicity [7,8].
Chronic liver injury, inflammation, fibrosis and, finally, liver
cirrhosis often precede the development of hepatocellular
carcinoma (HCC). The activation of hepatic stellate cells
(HSCs) is a central event in the development of hepatic fibrosis
and, ultimately, cirrhosis. Upon hepatic injury, HSCs transform
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to an active, highly proliferative myofibroblast-like phenotype
that is responsible for excessive matrix deposition in chronically
damaged livers [9,10]. The activity of the transcription factor
NFκB is increased during HSC activation and induces the
resistance of HSCs against apoptosis, which is critical for the
development and progression of hepatic fibrosis [11,12]. HSCs
also form the HCC stroma and promote tumorigenicity of HCC
cells [13–16]. Of note, we have shown that down-regulation of
MTAP and consequent elevation of intracellular and
extracellular MTA levels further induce the expression of
procancerous genes in HSCs [7].
In this study, we assessed the expression and function of
MTAP in chronic liver disease. Aside from a downregulation of
MTAP expression in hepatocytes of diseased livers, we
revealed strong MTAP expression in activated HSCs.
Moreover, we observed high MTA levels in activated HSCs
compared to hepatocytes indicating that in addition to the lower
MTAP expression and concomitant higher MTA levels in
hepatocytes also activated HSCs contribute to MTA levels in
diseased livers. Loss and gain of function studies confirmed
MTAP as critical regulator of MTA levels in activated HSCs.
Moreover, we identified MTAP regulated MTA levels as
modulator of NFκB activation and apoptosis resistance in
activated HSCs. Both promoter methylation and oxidative
stress were identified as critical regulators of MTAP expression
in activated HSCs. These findings may open new avenues to
the prognosis and treatment of hepatic fibrosis and cancer.
Materials and Methods
Chemicals
5′-Deoxy-5′-(methylthio)adenosine (MTA), arsenic trioxide
(As2O3), adenosine, periodate oxidized (AdOx), 5-azacytidine
(Aza), and N-acetyl-L-cysteine (NAC) were purchased from
Sigma-Aldrich Chemie GmbH (Deisenhofen, Germany).
Inhibitor of survivin YM155 was purchased from Selleckchem
(Munich, Germany).
Cells and cell culture
Primary human hepatocytes (PHH) and hepatic stellate cells
(HSCs) were isolated and cultured as described [17,18]. In vitro
activation of HSCs was achieved by cell culture on uncoated
tissue culture dishes as described [19].
Experimental murine models of hepatic injury
Bile duct ligation (BDL) or sham operations were performed
as described [19]. Mice were fed for 30 weeks either a control
or a NASH inducing diet containing 30% lard, 1.25%
cholesterol and 0.5% sodium cholate [20,21]. All procedures
followed the University of Regensburg guidelines for the care
and use of laboratory animals and the Institutional Animal Care
and Use Committee approved the study. Liver tissue
specimens were either fixed in 10% formalin or snap frozen in
liquid nitrogen and stored at -80°C for subsequent analysis.
Human tissue specimens
Formalin-fixed, paraffin-embedded human liver tissues for
immunohistochemical analysis were retrieved from the surgical
pathology files of the Institute of Pathology of the University of
Regensburg. Human liver tissue for cell isolation and
expression analyses was obtained according to the guidelines
of the charitable state controlled foundation HTCR (Human
Tissue and Cell Research), with the informed patients' written
consent, and the study was approved by the local ethics
committee of the University Regensburg. Experiments involving
human tissues and cells have been carried out in accordance
with The Code of Ethics of the World Medical Association
(Declaration of Helsinki).
Quantification of MTA and S-adenosyl-L-methionine
(SAM) by LC-ESI-MS/MS
MTA and S-adenosyl-L-methionine levels in cells, tissues
and in the supernatant of cultured cells were analyzed by liquid
chromatography-electrospray ionization-tandem mass
spectrometry (LC-ESI-MS/MS) [7].
Analysis of mRNA expression
Isolation of total cellular RNA and reverse transcription were
performed as described [22]. Quantitative real-time PCR was
performed with specific sets of primers applying LightCycler
technology (Roche, Mannheim, Germany) as described [22].
Protein analysis
Protein extraction and Western blotting were performed as
described [17,22] using monoclonal anti-MTAP and polyclonal
anti-survivin antibodies (both from Abcam, Cambridge, UK;
1:1.000); monoclonal phospho-IκB and phospho-p65
antibodies (Cell signaling Technology, Danvers, USA) were
used at a dilution of 1:1.000.
Immunohistochemical analysis of MTAP was performed as
described [7]. For immunohistochemical analysis cells were
fixed with 4% paraformaldehyde and permeabilized with 0.1%
Triton X 100. After blocking (5% BSA), cells were incubated
with anti-MTAP antibody (Abcam; 1:200), washed and then
incubated with secondary antibody (Cy3 conjugated goat anti
mouse IgG (H+L); 1:100; Invitrogen, Darmstadt, Germany). For
immunofluorescent costaining deparaffinized sections were
blocked with 1%BSA/PBS and incubated with anti MTAP
(Abcam 1:200) and anti α-sma (Abcam 1:400) antibody in 10%
FCS and 1%BSA/PBS. After washing sections were incubated
with Cy2- and TRITC conjugated secondary antibodies (1:200
Dianova, Hamburg, Germany) and a DAPI staining was
performed to identify cellular nuclei. Images were collected by
fluorescence microscopy using a Zeiss Axioskop2 mot plus
microscope (Zeiss, Göttingen, Germany).
Transfection experiments and luciferase reporter gene
assay
Cells were transfected with a MTAP expression plasmid or
empty control vector (pcDNA3) using the lipofectamine plus
method (Invitrogen) as described [23]. Applying the HiPerFect
method (Qiagen, Hilden, Germany), small interfering RNA
MTAP in Chronic Liver Disease
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(siRNA; Hs_MTAP_1,2 HP; all from Qiagen) was transiently
transfected into HSCs to deplete MTAP expression as
described [7]. The NFκB-luc plasmid (Promega) was used for
reporter gene assays. Transfection efficiency was normalized
to renilla luciferase activity by cotransfecting 0.1 µg of the
plasmid pRL-TK (Promega). All transfection experiments were
repeated at least three times.
Detection of cellular reactive oxygen species (ROS)
formation
ROS formation was analyzed with an assay applying cell-
permeant 2',7'-dichlorodihydrofluorescein diacetate
(H2DCFDA) according to the manufacturer's instructions
(Invitrogen). Briefly, cells were incubated with H2DCFDA at a
concentration of 100 μM for 30 min at 37°C, and after washing
with PBS, ROS formation was detected using a multi-well
fluorescence plate reader (Spectra Fluor Plus, Tecan,
Männedorf, Switzerland) with excitation and emission filters of
485 and 535 nm, respectively.
Analysis of apoptosis
Cells were stained simultaneously with FITC-conjugated
Annexin V and propidium iodide (both Promokine, Heidelberg,
Germany) and analyzed by ﬂow cytometry as described [18].
Further, the Apo-One Homogeneous Caspase-3/7 Assay
(Promega) was used to analyze caspase-3/7 activity according
to the manufacturer's instructions.
Statistical analysis
Results are expressed as mean ± standard error (range) or
percent. Comparison between groups was made using the
Student's unpaired t-test. A p value <0.05 was considered
statistically significant. All calculations were performed by using
the GraphPad Prism Software (GraphPad Software, Inc., San
Diego, USA).
Results
MTAP expression in chronic liver disease
First, we analyzed hepatic tissue from patients with alcoholic
liver disease and chronic viral infection and found significant
lower MTAP mRNA and protein expression in liver cirrhosis
compared to normal liver tissue (Figure 1A and 1B). In line
with the downregulation of MTAP, hepatic levels of MTA were
significantly higher in cirrhotic compared to normal human liver
tissue (Figure 1C). Next, we assessed patients with non-
alcoholic steatohepatitis (NASH), in which fibrosis was less
advanced. Expression of MTAP mRNA and protein were
similar to that in normal hepatic tissue (Figure 1D and 1E).
Nevertheless, levels of MTA were significantly higher in NASH
(Figure 1F). To verify these findings in experimental models of
chronic hepatic injury, we analyzed MTAP expression in mice
subjected to three weeks of bile duct ligation (BDL) or fed with
a NASH-inducing diet for 30 weeks. Similar as in human
cirrhosis, MTAP mRNA and protein expression were
significantly reduced in the BDL model (Figure 1G and 1H). In
murine NASH-livers, in concordance with the above human
data, hepatic levels of MTA were significantly elevated (Figure
1I) despite unaffected MTAP expression (Figure S1).
MTAP expression in hepatocytes and hepatic stellate
cells
Immunohistochemical analysis revealed reduced MTAP
expression in hepatocytes in both human cirrhotic liver tissue
(Figure 2A) and murine BDL-livers (Figure S2). In contrast,
myofibroblast-like cells in fibrotic septa showed a strong MTAP
immunosignal (Figure 2A). Coimmunofluorescent staining
confirmed that MTAP-expressing cells in fibrotic septa were
also positive for alpha-smooth-muscle actin (α-sma), a specific
marker for myofibroblasts such as activated hepatic stellate
cells (HSCs) (Figure S3). Also in vitro activated HSCs revealed
higher MTAP expression than primary human hepatocytes
(PHHs) (Figure 2B,C). Still, hepatocytes constitute the bulk
mass of hepatic cells in healthy as well as in diseased livers,
and thus, reduced MTAP expression in these cells likely
accounts for reduced MTAP levels observed in fibrotic liver
tissues. Furthermore, lowered MTAP in hepatocytes appeared
as one probable reason for increased MTA levels in diseased
livers. However, MTA levels were strikingly higher in activated
HSCs compared to PHHs in vitro (Figure 2D), and MTA levels
correlated significantly with collagen I (Figure 2E) and α-sma
(data not shown) mRNA expression in diseased human liver
tissue. Together these findings indicated that also activated
HSCs contribute to elevated MTA levels in diseased livers.
Higher levels of both MTAP expression and MTA in activated
HSCs compared to hepatocytes might be explained by a
generally more active methionine and adenine salvage
pathway in response to high proliferation and cellular
transdifferentiation in activated HSCs. In line with this, MTA
levels were below the detection limit in freshly isolated HSCs
and gradually increased during in vitro activation of HSCs
(Figure 2F). Also cellular levels of S-adenosyl-L-methionine
(SAM), a key product of the methionine metabolism,
progressively increased during the HSC activation in vitro
(Figure 2G). Similarly and in line with MTA, also SAM-levels in
human NASH and cirrhotic liver tissues were significantly
higher than in normal liver tissue (Figure S4). Together, these
findings may also explain the observed increase in MTA levels
in murine and human NASH tissues despite unaltered MTAP
expression (Figure 1D-F).
Functional role of MTAP in hepatic stellate cells
To gain insight into the functional role of MTAP in HSCs, we
transiently transfected activated HSCs with siRNA directed
against MTAP. This led to significantly reduced MTAP mRNA
and protein expression (Figure 3A,B; Figure S5) compared to
cells transfected with control siRNA. Furthermore, MTAP
suppression led to increased MTA levels in HSCs (Figure 3C).
Previously, we had shown that MTA affected NFκB activity in
hepatocellular carcinoma [7]. Here, we assessed whether MTA
affected this signaling pathway also in HSCs. MTAP-
suppressed HSCs revealed higher levels of phosphorylated
p65 (Figure 3D) and a NFκB reporter assay showed increased
NFκB activity in MTAP suppressed cells (Figure 3E). The NFκB
signaling pathway is increased during the activation of HSCs
MTAP in Chronic Liver Disease
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Figure 1.  MTAP expression and hepatic MTA levels in chronic liver disease.  Analysis of MTAP mRNA (A,D) and protein (B,E)
expression in liver specimens obtained from patients with cirrhosis (n=8) and NAFLD (n=11), respectively, and controls without liver
disease (n=6) by means of qRT-PCR and Western blotting. Hepatic MTA levels (C,F) in human liver tissues were determined by LC-
ESI-MS/MS. (G,H) MTAP expression in BDL-treated (n=5) and sham operated control mice (n=4). (I) Hepatic MTA levels in a
dietary murine NASH-model (n=5) compared to mice fed a control diet (n=5). In Western blot analysis, actin served as loading
control. (*p<0.05).
doi: 10.1371/journal.pone.0080703.g001
MTAP in Chronic Liver Disease
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Figure 2.  MTAP expression and MTA levels in hepatocytes and hepatic stellate cells.  (A) Immunohistochemical analysis of
MTAP in (I) control and (II,III) cirrhotic liver tissue (Magnification 200X and 400X). Measurement of MTAP mRNA (B) and protein (C)
levels in primary human hepatocytes (PHH) and activated HSCs (*p<0.05 compared to PHH). In Western blot analysis actin staining
was used to demonstrate equal protein loading. (D) Intracellular MTA levels measured by LC-ESI-MS/MS in PHHs compared to
activated HSCs. (E) Correlation of hepatic MTA levels of NAFLD patients with hepatic collagen I mRNA expression. Intracellular (F)
MTA and (G) S-adenosyl-L-methionine (SAM) levels in HSCs at different time points (days 2, 7, and 14) during the course of in vitro
activation measured with LC-ESI-MS/MS. (*p<0.05 compared to d2) .
doi: 10.1371/journal.pone.0080703.g002
MTAP in Chronic Liver Disease
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and protects these cells from apoptosis [11,24]. Consequently,
analysis of caspase3/7 activity (Figure 3F) and FACS analysis
(Figure 3G) revealed that HSCs with suppressed MTAP
expression were less susceptible to staurosporine (STS)
induced apoptosis compared to control cells.
In a second approach, we enhanced MTAP expression in
activated HSCs by transient transfection with a MTAP-
expression plasmid (Figure 4A,B). Consequently, MTAP
overexpressing HSCs revealed reduced MTA levels (Figure
4C) and reduced p65-phosphorylation (Figure 4D) and NFκB
reporter gene activity (Figure 4E). Furthermore, elevated MTAP
expression made HSCs more susceptible to STS induced
apoptosis (Figure 4F,G) than control vector (pcDNA3)
transfected cells.
Together, these data indicated that MTAP expression was a
critical regulator of MTA levels in activated HSCs, and herewith
significantly affected NFκB activity and apoptosis in HSCs.
Effect of MTA on hepatic stellate cells
Loss and gain of function studies indicated that MTAP
regulated MTA levels exhibit profibrogenic effects on HSCs.
Moreover, we observed that stimulation with 1µM MTA, i.e. a
MTA concentration found in diseased murine and human liver
tissues, induced the activation of HSCs in vitro as indicated by
increased collagen type I and α-sma expression (Figure 5A
and Figure S6). In contrast, previous studies by Simile et al.
and Latasa et al. showed that MTA stimulation in a dose range
between 25µM and 500µM or 200µM and 500µM, respectively,
caused impaired fibrogenic characteristics of activated HSCs
[25,26]. To unravel these putative discrepancies we stimulated
activated HSCs with MTA in a wide dose range comprising
MTA levels found in diseased liver tissues (up to 5µM) and
MTA doses as high as 1mM. In concentrations up to 5µM MTA
stimulation led to dose-dependent induction of CCL5 (also
called RANTES (Regulated on Activation, Normal T cell
Expressed and Secreted)) and CCL2 (also referred to as
monocyte chemotactic protein-1 (MCP-1)) expression, while
higher MTA doses reduced the expression of both chemokines
in activated HSCs (Figure 5B and Figure S7A). Similarly,
expression of collagen type I and transforming growth factor
beta (TGF-β) was induced by lower MTA doses but reduced in
response to higher MTA doses (Figure S7B,C). These findings
indicated a nonmonotonic dose-response relationship between
MTA levels and proinflammatory and profibrogenic gene
expression in activated HSCs. While the studies of Simile et al.
and Latasa et al. [25,26] comprehensively assessed the effects
of exogenously applied MTA doses, we subsequently focused
on the assessment of the effects of (endogenous) MTA levels
found in diseased livers. In this dose range, MTA caused a
time-dependent induction of CCL5 (Figure 5C) and MCP-1
(data not shown) expression in activated HSCs in vitro. Rapid
induction of chemokine expression pointed to an effect on
transcriptional regulation, and NFκB is a known critical
regulator of these chemokines [27]. MTA stimulation of HSCs
induced a dose-dependent phosphorylation of IκB-α (Figure
5D) and activation of NFκB-reporter gene activity (Figure 5E).
Moreover, analysis of caspase3/7 activity and FACS analysis
revealed, that MTA stimulation increased the resistance of
activated HSCs towards apoptosis (Figure 5F,G).
Functional effect of MTAP/MTA on survivin expression
in activated hepatic stellate cells
Manipulation of MTAP expression or MTA stimulation did not
significantly affect BAX, BCLXL and XIAP expression in
activated HSCs (Figure S8). However, suppression of MTAP
expression (Figure 6A) and wild-type HSCs stimulated with
MTA (Figure 6B) revealed an increased expression of survivin.
In contrast, survivin expression was downregulated in MTAP
overexpressing HSCs compared to pcDNA3 transfected control
cells (Figure 6C). Survivin is a target of NFκB [28] and can
prevent caspase-induced apoptosis [29]. This suggested that
the regulation of this anti-apoptotic factor accounted at least in
part for the effects of the manipulation of MTAP levels and
MTA stimulation, respectively, on apoptosis resistance of
HSCs. Accordingly, pretreatment with the survivin inhibitor
YM-155 abolished the apoptosis protecting effect of MTA
stimulation in HSCs (Figure 6D). In summary, these findings
indicated, that NFκB-mediated regulation of survivin expression
was responsible for the effects of MTAP and MTA on apoptosis
resistance of activated HSCs.
Regulation of MTAP expression in activated hepatic
stellate cells
Next, we analyzed the mechanisms that regulate MTAP
expression in activated HSCs. We had shown previously, that
promoter methylation caused downregulation of MTAP
expression in HCC cells [30]. To assess whether this
mechanism also affected MTAP expression in HSCs, we
incubated activated HSCs with the demethylating agent 5-
azacytidine (5-Aza) and found that this treatment enhanced
MTAP expression in a dose dependent manner (Figure 7A).
Liver damage is characterized by increased formation of
reactive oxygen species (ROS), and oxidative stress has been
shown to induce promoter methylation [31,32]. Arsenic trioxide
(AT) induces ROS production via up-regulation of NADPH
oxidase [33] (Figure S9), and AT treatment inhibited MTAP
mRNA and protein expression (Figure 7B,C). Preincubation
with the ROS-scavenger N-Acetyl-L-Cysteine (NAC) abrogated
AT-induced downregulation of MTAP mRNA and protein
(Figure 7B,C). Further, stimulation with hydrogen peroxide
dose dependently downregulated MTAP in HSCs (Figure S10)
confirming that oxidative stress caused a downregulation of
MTAP in HSCs. In contrast, pretreatment with
methyltransferase inhibitor adenosine periodate oxidized
(AdOx) abolished ROS induced MTAP downregulation (Figure
7D). On the contrary, AT stimulation increased survivin
expression in activated HSCs, and this induction was blunted
by AdOx treatment (Figure 7E). Together, these data indicate
that epigenetic mechanisms account at least in part for the
increased MTAP expression while oxidative stress causes a
downregulation of MTAP expression in activated HSCs, and
herewith functionally affect the profibrogenic phenotype of
these cells.
MTAP in Chronic Liver Disease
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Figure 3.  Suppression of MTAP in activated hepatic stellate cells with siRNA.  Activated HSCs were transfected with siRNA
against MTAP (siRNA1 and siRNA2) or control siRNA. (A,B) Analysis of MTAP expression by qRT-PCR and Western blotting. (C)
Quantification of cellular MTA levels by means of LC-ESI-MS/MS. (D) Western blot analysis of phosphorylated p65. Actin staining
was used to demonstrate equal protein loading. (E) NFκB reporter gene assay. (F) Analysis of caspase3/7 activity in HSCs with and
without staurosporine (STS) treatment (500nM; 4h) to induce apoptosis. (G) Assessment of STS-induced apoptosis by flow
cytometric analysis of annexin V-FITC / propidium iodide stained cells. Depicted are mean percentages of total apoptotic cells from
3 independent experiments. (*p<0.05 compared to ctrl. siRNA).
doi: 10.1371/journal.pone.0080703.g003
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Figure 4.  Overexpression of MTAP in activated HSCs.  Activated HSCs were transiently transfected with control vector
(pcDNA3) and an MTAP expression vector (MTAP). (A,B) Analysis of MTAP expression by qRT-PCR and Western blotting. (C)
Quantification of cellular MTA levels by LC-ESI-MS/MS. (D) Western blot analysis of phosphorylated p65. Actin staining was used to
demonstrate equal protein loading. (E) NFκB reporter gene assay. (F) Analysis of caspase3/7 activity in HSCs with and without
staurosporine (STS) treatment (500nM; 4h) to induce apoptosis. (G) Assessment of STS-induced apoptosis by flow cytometry
applying annexin V and propidium iodide staining. Depicted are mean percentages of total apoptotic cells from 3 independent
experiments. (*p<0.05 compared to pcDNA3).
doi: 10.1371/journal.pone.0080703.g004
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Figure 5.  Effect of MTA stimulation on hepatic stellate cells.  (A) Effect of MTA on hepatic stellate cell activation in vitro. Two
days after isolation HSC were incubated with MTA (1µm) for 72h. Subsequently, collagen I mRNA expression was analyzed by
quantitative PCR. (B,C) CCL5 mRNA expression in activated HSCs treated with MTA at different doses and for different time
intervals. (D) Analysis of phosphorylated IκBα by Western Blot analysis and (E) NFκB reporter gene assay in activated HSCs
stimulated with MTA (1µM). (F) Analysis of caspase3/7 activity in MTA (1µM) treated HSCs with and without staurosporine (STS)
treatment (500 nM; 4h) to induce apoptosis. (G) Assessment of STS-induced apoptosis in MTA (1µM) treated and control HSCs by
annexin V-FITC / propidium iodide staining and flow cytometry. Depicted are mean percentages of total apoptotic cells from 3
independent experiments. (*p<0.05 compared to control).
doi: 10.1371/journal.pone.0080703.g005
MTAP in Chronic Liver Disease
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Regulation of MTAP expression and MTA effects in
hepatocytes
Next, we wanted to analyze whether the molecular
mechanisms identified to regulate MTAP expression in HSCs
are also responsible for the observed downregulation of MTAP
expression in hepatocytes in cirrhotic liver tissues (Figure 2A
and Figure S2). In contrast to HSCs (Figure 7A), treatment with
the demethylating agent 5-Aza did not significantly affect MTAP
Figure 6.  Functional effect of MTAP/MTA on survivin expression in activated hepatic stellate cells.  Survivin mRNA and
protein expression in activated HSCs (A) transfected with MTAP siRNA or control siRNA, (B) stimulated with MTA, and (C)
transfected with a MTAP expression plasmid or empty vector (pcDNA3); (*p<0.05 compared to ctrl.; ctrl. siRNA; 0µM MTA or
pcDNA3, respectively). (D) Assessment of caspase3/7 activity in MTA-treated HSCs with and without preincubation with the survivin
inhibitor YM155 (5µM) and with and without staurosporine (STS 500 nM; 4h) treatment to induce apoptosis. (*p<0.05 compared to
ctrl.).
doi: 10.1371/journal.pone.0080703.g006
MTAP in Chronic Liver Disease
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expression in primary murine and human hepatocytes (Figure
8A and Figure S11). However, expression of proliferator-
activated receptor-gamma (PPAR-gamma), a gene known to
be regulated by promoter-methylation [34,35], significantly
increased in response to 5-Aza treatment (Figure 8B). To
assess the role of oxidative stress in MTAP regulation in
hepatocytes, cells were incubated with arsenic trioxide. This
inducer of ROS production significantly reduced MTAP
expression in primary hepatocytes (Figure 8C,D). These
findings indicate, that oxidative stress, a known inducer of
Figure 7.  Regulation of MTAP expression in activated hepatic stellate cells.  MTAP expression in activated HSCs treated with
5-azacytidine (1-100µM) (A) or As2O3 (AT) (10µM) and NAC (10mM) (B,C). MTAP and survivin mRNA expression in HSCs
stimulated with methylation inhibitor AdOx (50µM) alone and in combination with AT (10µM) (D,E). (*p<0.05 compared to ctrl.;
#p<0.05 compared to AT).
doi: 10.1371/journal.pone.0080703.g007
MTAP in Chronic Liver Disease
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hepatocellular inflammation and fibrosis [36,37], significantly
impairs MTAP expression in both activated HSCs and
hepatocytes, and herewith, also greatly affects hepatic MTA
levels. To analyze whether MTA also exhibits similar pro-
inflammatory effects on hepatocytes as observed in HSCs,
primary murine hepatocytes were stimulated with MTA in a
wide dose-range comprising MTA levels found in diseased liver
tissues and pharmacological doses MTA doses as high as
500µM. In concentrations up to 5µM MTA stimulation led to
induction of CCL5 expression, while higher MTA doses
reduced the expression of this chemokine in primary murine
hepatocytes (Figure 8E). Similarly as in HSCs, these findings
indicate a nonmonotonic dose-response relationship between
MTA levels and proinflammatory gene expression also in
hepatocytes.
Discussion
Recently, we have shown downregulation and tumor
suppressor activity of MTAP in hepatocellular carcinoma (HCC)
[7]. Here, we expanded our investigation on chronic liver
disease, which is the major HCC precondition. The observed
downregulation of MTAP mRNA expression in cirrhotic human
livers and experimental models of liver cirrhosis was in line with
a previous study by Berasain et al. [8]. Here, we confirmed this
finding at the protein level, and applying immunohistochemistry
we revealed that hepatocytes of cirrhotic livers have lower
MTAP expression than hepatocytes in normal liver tissue. In
contrast, we found strong MTAP expression in activated HSCs
in cirrhotic livers. Moreover, we demonstrated that not only
MTAP but also its metabolite MTA are abundant in activated
HSCs. This may be caused by an upregulation of polyamine
biosynthesis in response to enhanced proliferation and cellular
transdifferentiation during the course of HSC activation. In line
with this, we found increased MTA as well as SAM levels
during in vitro activation of HSCs. Interestingly, fully activated
HSCs showed markedly higher MTA levels than hepatocytes in
vitro. Moreover, hepatic MTA levels strongly correlated with
collagen I expression in diseased hepatic tissue. Together
these findings indicated that also in vivo activated HSCs
significantly contribute to MTA abundance in fibrotic livers
despite their relatively lower quantity compared to hepatocytes,
which are the main cellular source of total MTA in normal liver
tissue. Still, our data cannot define the exact contribution of
activated HSCs and hepatocytes to MTAP and MTA levels in
diseased livers. Likely the contribution also varies during the
course of chronic liver disease and depending on the type of
liver injury. Thus, differences in the cellular sources of MTAP
and MTA could also account for enhanced MTA levels in
NASH, although MTAP levels in total liver tissue were similar
as in normal liver tissue. Furthermore, this may be an
explanation why Berasain et al. did not find MTA accumulation
in the model of carbon tetrachloride (CCl4)-induced liver injury
in spite of a compromised expression of MTAP [8]. In addition,
it has to be considered that MTA is produced during polyamine
biosynthesis from S-adenosylmethionine (SAM), its metabolic
precursor. Interestingly, Berasain et al. found that SAM was
strongly reduced in CCl4-treated rats, and herewith, identified
one further potential mechanism why reduced MTAP levels in
diseased livers may not always coincide with enhanced MTA
levels in particular experimental models.
In the present study, we observed increased MTA levels in
two experimental models of hepatic injury as well as in patients
with NASH and cirrhosis of different origin. Stimulation of
activated HSCs with MTA at concentrations similar to those
found in diseased liver tissues caused increased profibrogenic
gene expression and NFκB activation, as well as enhanced
apoptosis resistance. In contrast to our findings, some groups
have reported proapoptotic effects of MTA on hepatoma cells
[38], and found antifibrotic effects of MTA on HSCs in vitro and
in experimental models of hepatic fibrosis [25,26]. However, in
those studies significantly higher, pharmacological doses had
been administered, whereas the MTA levels achieved here
mirrored endogenous hepatic levels. Moreover,
pharmacological doses of MTA have been shown to exhibit
protective effects on hepatocytes in vitro [38–40], while MTA
accumulation in HCC promotes tumorigenicity [7]. Our in vitro
findings clearly showed a biphasic effect of MTA stimulation
levels on profibrogenic response in activated HSCs and
hepatocytes, and it is reasonable that also in other cells such a
nonmonotonic dose-response relationship exists. Together,
these findings indicate that hepatic effects of MTA are a
double-edged sword and warrant the exercise of caution in the
pharmacological use of MTA in treating liver disease, as
pharmacological levels may drop to levels at which
profibrogenic and pro-tumorigenic effects predominate.
In addition to exogenous MTA stimulation also manipulation
of MTAP expression and subsequent alterations of intracellular
MTA levels functionally affected activated HSCs. Survivin has
been described as a NFκB target gene in tumor cells [28], and
De Minicis et al. described increased survivin expression in
HSCs isolated from murine fibrosis models [41]. Here, we
showed that survivin functionally affected apoptosis resistance
of activated HSCs and identified this member of the Inhibitor of
Apoptosis (IAP) family as a transcriptional target of exogenous
MTA mediated NFκB activation in activated HSCs. Moreover,
loss and gain of function studies revealed that MTAP-regulated
levels of intracellular MTA affect NFκB activity and survivin
expression in activated HSCs. NFκB activity in HSCs is critical
for their resistance against apoptosis, and herewith, the extent
of fibrosis in chronic liver injury [12]. Hepatic fibrosis and
cirrhosis are HCC preconditions, and we have shown
downregulation and tumor suppressor activity of MTAP in HCC
[7]. Together, these findings suggest (induction of) MTAP as
therapeutic strategy against both fibrosis and cancerogenesis
in chronic liver disease. Noteworthy, we found that promoter
methylation is a critical regulator of MTAP expression in HSCs
similar as we and others have shown before in HCC cells
[8,30]. DNA methylation inhibitors have been suggested for
treatment of HCC [42] and have been shown to inhibit HSC
activation and fibrogenesis [43]. Our study unraveled a novel
mechanism by which epigenetic mechanisms critically affect
the fibrogenic potential of HSCs. Furthermore, we identified
oxidative stress to impair MTAP expression in HSCs as well as
in hepatocytes. This finding is complementary to a previous
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Figure 8.  Regulation of MTAP expression and MTA effects on hepatocytes.  (A,B) MTAP and PPAR-gamma mRNA
expression in murine hepatocytes treated with 5-azacytidine (10µM and 100µM). (C,D) MTAP mRNA and protein expression in
murine hepatocytes treated with As2O3 (AT) (10µM). (E) CCL5 mRNA expression in murine hepatocytes stimulated with different
doses of MTA. (*p<0.05 compared to ctrl.).
doi: 10.1371/journal.pone.0080703.g008
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study by Fernandez-Irigoyen et al., who demonstrated redox
regulation of MTAP activity in hepatocytes [44].
In conclusion, we identified regulation of MTAP expression
and corresponding MTA levels as a novel mechanism affecting
profibrogenic gene expression, NFκB activity and apoptosis
resistance in HSCs. This may be exploited for the prognosis or
treatment of fibrosis progression in chronic liver disease.
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